SCHEDULE 13G/A: Morgan Stanley Discloses Significant 8.3% Stake in NeuroPace Inc. Common Stock

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have disclosed a combined beneficial ownership of 8.3% of NeuroPace Inc.'s common stock as of December 31, 2024.

Summary

• Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have filed an Amendment No. 2 to Schedule 13G, detailing their beneficial ownership in NeuroPace Inc.
• As of December 31, 2024, Morgan Stanley beneficially owns 2,489,391 shares of NeuroPace Inc. common stock, representing 8.3% of the class.
• Morgan Stanley Capital Services LLC, a wholly-owned subsidiary of Morgan Stanley, beneficially owns 2,455,896 shares, representing 8.2% of the class.
• The filing explicitly states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of NeuroPace Inc.

Sentiment

Score: 6

Explanation: The filing indicates a significant, passive institutional stake by Morgan Stanley in NeuroPace Inc., which is generally a positive signal of confidence from a major financial entity. However, it provides no operational or financial performance details from the issuer.

Positives

• A major financial institution, Morgan Stanley, holds a significant 8.3% stake in NeuroPace Inc., indicating institutional interest or confidence.
• The filing confirms that the shares are held in the ordinary course of business, suggesting a passive investment rather than an activist stance.

Future Outlook

NA

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

This filing indicates that NeuroPace Inc. continues to attract significant institutional investment from major financial players like Morgan Stanley. Such substantial holdings by a prominent investment bank can signal market confidence in the company's long-term prospects within the medical device or neuroscience sector, particularly for companies focused on neuromodulation therapies.

Comparison to Industry Standards

• This document is a standard Schedule 13G filing, which is a regulatory requirement for institutional investors acquiring more than 5% of a company's stock.
• The percentage of ownership (8.3%) is a significant stake for an institutional investor, placing Morgan Stanley among the larger shareholders of NeuroPace Inc. without necessarily implying an activist role, as stated in the filing.
• No specific comparable companies, projects, or results are mentioned in the document to allow for a direct comparison of NeuroPace Inc.'s performance against industry standards.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional holder like Morgan Stanley may be viewed positively, potentially increasing investor confidence and liquidity.

Next Steps

• Morgan Stanley will continue to file amendments to Schedule 13G as required by SEC regulations if their beneficial ownership percentage changes significantly.

Key Dates

Keywords

NeuroPace Inc, Morgan Stanley, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Passive Investment